Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease

Journal of the Formosan Medical Association

Volumn 113, Issue 4, 2014, Pages 219-226

  Chen, Ping Min ^a   Lai, Tai Shuan ^a   Chen, Ping Yu ^a,b   Lai, Chun Fu ^a   Wu, VinCent ^a   Chiang, Wen Chih ^a   Chen, Yung Ming ^a   Wu, Kwan Dun ^a   Tsai, Tun Jun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Chronic kidney disease; Pentoxifylline; Renal outcome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PENTOXIFYLLINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PERITONEAL DIALYSIS; PROTEINURIA; RENAL PROTECTION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; DRUG EFFECTS; KIDNEY; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PENTOXIFYLLINE; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84897107780     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2014.01.002     Document Type: Article

References (37)

1. Guh J.Y., Chen H.C., Tsai J.F., Chuang L.Y. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 2007, 49:626-633.
2. Lin Wu F.L., Chen Y.M., Lai T.S., Shen L.J., Ho Y.F., Lee Y.T., et al. Does Chinese herb nephropathy account for the high incidence of end-stage renal disease in Taiwan?. Nephron Clin Pract 2012, 120:c215-c222.
3. Yang H.Y., Wang J.D., Lo T.C., Chen P.C. Increased risks of upper tract urothelial carcinoma in male and female Chinese herbalists. J Formos Med Assoc 2011, 110:161-168.
4. Chang F.C., Chou Y.H., Chen Y.T., Lin S.L. Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis. J Formos Med Assoc 2012, 111:589-598.
5. Gomez I.G., Grafals M., Portilla D., Duffield J.S. MicroRNAs as potential therapeutic targets in kidney disease. J Formos Med Assoc 2013, 112:237-243.
6. Yeh P.Y., Liao F.L., Lin S.L. Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?. J Formos Med Assoc 2013, 112:655-656.
7. Lin C.M., Yang M.C., Hwang S.J., Sung J.M. Progression of stages 3b-5 chronic kidney disease-preliminary results of Taiwan National Pre-ESRD Disease Management Program in Southern Taiwan. J Formos Med Assoc 2013, 112:773-782.
8. Wu I.W., Wang S.Y., Hsu K.H., Lee C.C., Sun C.Y., Tsai C.J., et al. Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality-a controlled cohort study based on the NKF/DOQI guidelines. Nephrol Dial Transplant 2009, 24:3426-3433.
9. Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118:577-581.
10. Ravid M., Lang R., Rachmani R., Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
11. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
12. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
13. Jafar T.H., Schmid C.H., Landa M., Giatras I., Toto R., Remuzzi G., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
14. Hou F.F., Zhang X., Zhang G.H., Xie D., Chen P.Y., Zhang W.R., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140.
15. Kamper A.L., Strandgaard S., Leyssac P.P. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992, 5:423-430.
16. Lin S.L., Chen R.H., Chen Y.M., Chiang W.C., Lai C.F., Wu K.D., et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 2005, 16:2702-2713.
17. Lin S.L., Chen Y.M., Chien C.T., Chiang W.C., Tsai C.C., Tsai T.J. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 2002, 13:2916-2929.
18. Chen Y.M., Ng Y.Y., Lin S.L., Chiang W.C., Lan H.Y., Tsai T.J. Pentoxifylline suppresses renal tumour necrosis factor-α and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004, 19:1106-1115.
19. Han K.H., Han S.Y., Kim H.S., Kang Y.S., Cha D.R. Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy. Inflammation 2010, 33:137-143.
20. Usta Y., Ismailoglu U.B., Bakkaloglu A., Orhan D., Besbas N., Sahin-Erdemli I., et al. Effects of pentoxifylline in adriamycin-induced renal disease in rats. Pediatr Nephrol 2004, 19:840-843.
21. Goicoechea M., García de Vinuesa S., Quiroga B., Verdalles U., Barraca D., Yuste C., et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol 2012, 25:969-975.
22. Chen Y.M., Lin S.L., Chiang W.C., Wu K.D., Tsai T.J. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 2006, 69:1410-1415.
23. McCormick B.B., Sydor A., Akbari A., Fergusson D., Doucette S., Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008, 52:454-463.
24. Rodriguez-Morán M., González-González G., Bermúdez-Barba M.V., Medina de la Garza C.E., Tamez-Pérez H.E., Martínez-Martínez F.J., et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol 2006, 66:3-10.
25. Harmankaya O., Seber S., Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 2003, 25:465-470.
26. Renke M., Tylicki L., Rutkowski P., Knap N., Zietkiewicz M., Neuwelt A., et al. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease-placebo controlled, randomized, cross-over study. Acta Biochim Pol 2010, 57:119-123.
27. Lin S.L., Chen Y.M., Chiang W.C., Wu K.D., Tsai T.J. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 2008, 52:464-474.
28. Perkins R.M., Aboudara M.C., Uy A.L., Olson S.W., Cushner H.M., Yuan C.M. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009, 53:606-616.
29. Ghorbani A., Omidvar B., Beladi-Mousavi S.S., Lak E., Vaziri S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 2012, 32:790-796.
30. Navarro J.F., Mora C., Rivero A., Gallego E., Chahin J., Macía M., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 1999, 33:458-463.
31. Diskin C.J., Stokes T.J., Dansby L.M., Radcliff L., Carter T.B. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?. J Nephrol 2007, 20:410-416.
32. Roozbeh J., Banihashemi M.A., Ghezlou M., Afshariani R., Salari S., Moini M., et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail 2010, 32:172-178.
33. Aminorroaya A., Janghorbani M., Rezvanian H., Aminian T., Gharavi M., Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005, 99:c73-c77.
34. Navarro J.F., Mora C., Muros M., García J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005, 16:2119-2126.
35. Badri S., Dashti-Khavidaki S., Ahmadi F., Mahdavi-Mazdeh M., Abbasi M.R., Khalili H. Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial. Clin Drug Investig 2013, 33:215-222.
36. Navarro J.F., Milena F.J., Mora C., León C., García J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006, 26:562-570.
37. O'Hare A.M., Choi A.I., Bertenthal D., Bacchetti P., Garg A.X., Kaufman J.S., et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007, 18:2758-2765.